{
    "clinical_study": {
        "@rank": "67032", 
        "arm_group": [
            {
                "arm_group_label": "Aspirin+Clopidogrel/Digoxin(oral)", 
                "arm_group_type": "Experimental", 
                "description": "Aspirin: Day 1 ~ Day 59(~65; till the EGC) Clopidogrel: Day -3, 26, 54 Digoxin: Day -2, 27, 55"
            }, 
            {
                "arm_group_label": "Aspirin+Clopidogrel/Digoxin(IV)", 
                "arm_group_type": "Experimental", 
                "description": "Aspirin: Day 1 ~ Day 59(~65; till the EGC) Clopidogrel: Day -3, 26, 54 Digoxin: Day -2, 27, 55"
            }
        ], 
        "brief_summary": {
            "textblock": "Clinical trial to evaluate the influence of multiple aspirin administration on PK and PD of\n      co-administered drugs"
        }, 
        "brief_title": "Clinical Trial to Evaluate the Influence of Genotype and DDIs of Aspirin on the PK/PD of Clopidogrel and PK of Digoxin", 
        "completion_date": {
            "#text": "December 2013", 
            "@type": "Anticipated"
        }, 
        "condition": "DRUG REACTIONS", 
        "detailed_description": {
            "textblock": "Clinical trial to evaluate the influence of genotype of drug metabolizing enzyme or\n      transporter and drug-drug interactions of aspirin co-administration on the pharmacokinetics\n      / pharmacodynamics of clopidogrel and pharmacokinetics of digoxin in healthy volunteers"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Healthy male subjects aged 20 - 45 years.\n\n          -  A body weight in the range of 50 kg (inclusive) - 90 kg (exclusive) and a body mass\n             index (BMI) in the range 18.5 kg/m2 (inclusive) - 27 kg/m2 (inclusive).\n\n          -  Sufficient ability to understand the nature of the study and any hazards of\n             participating in it. Provide written informed consent after being fully. informed\n             about the study procedures.\n\n        Exclusion Criteria:\n\n          -  Presence or history of hypersensitivity or allergic reactions to drugs including\n             investigational product (clopidogrel, digoxin or aspirin)\n\n          -  Clinically relevant abnormal medical history that could interfere with the objectives\n             of the study.\n\n          -  A subject with history of gastrointestinal disease or surgery (except simple\n             appendectomy or repair of hernia), which can influence the absorption of the study\n             drug.\n\n          -  A subject whose lab test results are as follows; Platelet count or PT, aPTT < 0.9 x\n             lower limit of reference range of > 1.1 x upper limit of reference range.\n\n          -  A subject whose SBP is over 160 mmHg or below 90 mmHg and DBP is over 100 mmHg or\n             below 50 mmHg.\n\n          -  Clinically significant abnormal findings of ECG during screening test.\n\n          -  Presence or history of drug abuse or positive result in urine drug screening test.\n\n          -  Participation in other clinical trial within 2 months before first dose.\n\n          -  Use of CYP inducer (ex. rifampin) within 4 weeks before first dose.\n\n          -  Use of a prescription medicine, herbal medicine within 2 weeks or over-the-counter\n             medication or vitamin substances within 1 week before first dose.\n\n          -  Use of grapefruit juice within 1 week before first dose.\n\n          -  Blood donation during 2 months or apheresis during 1 month before the study.\n\n          -  Use of alcohol over 21 units/weeks\n\n          -  Smoking of more than 10 cigarettes/days within 3 months before first dose.\n\n          -  Subject judged not eligible for study participation by investigator."
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "45 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "24", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 15, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01775839", 
            "org_study_id": "PGX_Clopidogrel_002"
        }, 
        "intervention": [
            {
                "arm_group_label": "Aspirin+Clopidogrel/Digoxin(oral)", 
                "description": "oral administration of digoxin", 
                "intervention_name": "Aspirin+Clopidogrel/Digoxin(oral)", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Aspirin", 
                    "Clopidogrel", 
                    "Digoxin"
                ]
            }, 
            {
                "arm_group_label": "Aspirin+Clopidogrel/Digoxin(IV)", 
                "description": "intravenous administration of digoxin", 
                "intervention_name": "Aspirin+Clopidogrel/Digoxin(IV)", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Aspirin", 
                    "Clopidogrel", 
                    "Digoxin"
                ]
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Aspirin", 
                "Ticlopidine", 
                "Clopidogrel", 
                "Digoxin"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "January 22, 2013", 
        "location": {
            "contact": {
                "email": "ijjang@snu.ac.kr", 
                "last_name": "In-Jin Jang, MD", 
                "phone": "+82-2-2072-1930"
            }, 
            "facility": {
                "address": {
                    "city": "Seoul", 
                    "country": "Korea, Republic of", 
                    "zip": "110-744"
                }, 
                "name": "Seoul National University Hospital Clinical Trials Center"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "2", 
        "official_title": "Clinical Trial to Evaluate the Influence of Genotype of Drug Metabolizing Enzyme or Transporter and Drug-drug Interactions of Aspirin Co-administration on the PK/PD of Clopidogrel and PK of Digoxin in Healthy Volunteers", 
        "overall_contact": {
            "email": "ijjang@snu.ac.kr", 
            "last_name": "In-Jin Jang, MD", 
            "phone": "+82-2-2072-1930"
        }, 
        "overall_official": {
            "affiliation": "SNUH", 
            "last_name": "In-Jin Jang, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Korea: Institutional Review Board", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "December 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "(Clopidogrel)Predose and 10, 20, 30, 40, 50 min, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 10, 12, 24 h postdose on Week 0, 4, 8 (Digoxin) Predose and 10, 20, 30, 45 min, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, 48 h postdose on Week 0, 4, 8", 
            "measure": "AUC and Cmax of Clopidogrel and Digoxin", 
            "safety_issue": "No", 
            "time_frame": "pre- and post dose of Clopidogrel, Digoxin administration"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01775839"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Seoul National University Hospital", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Seoul National University Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "January 2013"
    }
}